Results 271 to 280 of about 1,543,340 (337)
Unleashing the Power of Machine Learning in Nanomedicine Formulation Development
A random forest machine learning model is able to make predictions on nanoparticle attributes of different nanomedicines (i.e. lipid nanoparticles, liposomes, or PLGA nanoparticles) based on microfluidic formulation parameters. Machine learning models are based on a database of nanoparticle formulations, and models are able to generate unique solutions
Thomas L. Moore +7 more
wiley +1 more source
We introduce a nucleic acid nanoparticle (NANP) platform designed to be rrecognized by the human innate immune system in a regulated manner. By changing chemical composition while maintaining constant architectural parameters, we identify key determinants of immunorecognition enabling the rational design of NANPs with tunable immune activation profiles
Martin Panigaj +21 more
wiley +1 more source
A microphysiological lung fibrosis model recapitulates myofibroblast–vascular interactions. Induced myofibroblasts and patient‐derived IPF fibroblasts impair angiogenesis and increase vascular permeability via TGF‐β1–driven signaling. Pharmacological interventions with SB 431542 and VEGF supplementation restore vascular morphology and barrier function.
Elena Cambria +7 more
wiley +1 more source
A unidirectional cerebral organoid–organoid neural circuit is established using a microfluidic platform, enabling controlled directional propagation of electrical signals, neuroinflammatory cues, and neurodegenerative disease–related proteins between spatially separated organoids.
Kyeong Seob Hwang +9 more
wiley +1 more source
A spleen‐targeting hybrid nanoplatform (RBCMV‐LNP‐RP) harnessing erythrophagocytosis mimics senescent red blood cell clearance to achieve spleen‐specific delivery of rapamycin. This biomimetic system enables selective accumulation in splenic macrophages, orchestrating systemic immune reprogramming and promoting mucosal healing in an inflammatory bowel ...
Jun Kwon +10 more
wiley +1 more source
A bimetallic Mn–Ca nanoreactor (MCC) is developed as a non‐nucleotide STING nanoagonist for cancer metalloimmunotherapy. MCC induces Ca2+ overload and hydroxyl radical generation, resulting in mitochondrial damage and mtDNA release. The released mtDNA cooperates with Mn2+ to robustly activate cGAS–STING signaling.
Xin Wang Mo +7 more
wiley +1 more source

